Acute coronary syndrome (ACS) results from thrombus formation at the site of ruptured or eroded atherosclerotic plaques, which restricts coronary blood flow resulting in myocardial ischemia and injury. Thrombosis is initiated by the exposure of tissue factor and collagen to the circulating blood, which leads simultaneously to local triggering of the coagulation cascade and activation and adhesion of platelets. Activated platelets release secondary agonists, including thromboxane and ADP, which recruit additional waves of platelet adhesion that facilitate thrombus growth. Given their central pathogenic importance, pharmacological inhibition of both platelet activation and thrombin generation have long been cornerstone treatments for the full spectrum of ACS.
Current European and North America guidelines provide a class I recommendation for the administration of dual antiplatelet therapy to patients presenting with non-ST elevation ACS consisting of aspirin to inhibit platelet thromboxane production and an ADP (P2Y 12 ) receptor antagonist, such as the thienopyridine clopidogrel, to prevent secondary platelet activation. 1 2 In the linked research article, Bellemain-Appaix and colleagues (doi:10.1136/bmj.g6269) explore how timing of treatment might influence important clinical outcomes.
Current guidance relies heavily on the seminal Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial, which demonstrated in 12 562 patients with non-ST elevation ACS that early and sustained treatment with clopidogrel plus aspirin reduced the 12 month composite incidence of cardiovascular death, non-fatal myocardial infarction, and stroke by 20% compared with aspirin treatment alone. 3 The clinical benefit of dual antiplatelet therapy, which was seen in patients treated with either a conservative or early invasive strategy, was offset by a 38% increased risk of major bleeding.
Since the publication of the CURE trial in 2001, treatment of non-ST elevation ACS has evolved in several important ways: First, there has been more widespread adoption of an early invasive treatment strategy, in which high risk patients often undergo cardiac catheterization and percutaneous coronary intervention (PCI) within hours, rather than within days, of presentation. 4 Second, there is a better understanding of clopidogrel metabolism, which has helped to optimise dosing protocols during PCI. 5 Third, newer ADP receptor antagonists, such as prasugrel and ticagrelor, are now available that achieve a more rapid, reliable, and potent degree of platelet inhibition compared with clopidogrel. Myocardial Infarction (ACCOAST) trial, which found that treating patients with anticoagulation therapy and aspirin but withholding prasugrel administration until immediately before PCI did not alter clinical outcome and was associated with half the incidence of major bleeding compared with administration of prasugrel earlier at the time of presentation. 7 While provocative, it is not immediately clear if the results of the ACCOAST study can be generalized to the larger spectrum of patients presenting with non-ST elevation ACS or those treated with other ADP receptor antagonists, particularly clopidogrel.
Bellemain-Appaix and colleagues begin to address these questions by performing a meta-analysis of seven studies involving 33 917 patients with non-ST elevation ACS treated either with early invasive or conservative strategies to determine if the timing of thienopyridine (clopidogrel or prasugrel) administration influenced patient outcomes, including deaths, bleeding, and major adverse events. 8 In an analysis of the entire cohort of patients, some of whom were treated conservatively and did not undergo cardiac catheterization, the authors found that 30 day mortality was no different among patients receiving up-front administration of a thienopyridine compared with those who may have received it later or not at all, though major bleeding was 32% higher. In an arguably cleaner analysis of patients undergoing PCI, administration of a thienopyridine before coronary angiography or PCI likewise did not reduce the risk of death but did increase the risk of bleeding by 23% compared with receiving a thienopyridine at the time of or shortly after PCI.
The authors also found that the risk of major adverse cardiac events was slightly lower with thienopyridine pretreatment (odds ratio 0.84 (95% confidence interval 0.69 to 1.01), P=0.02), but 
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this trend did not reach statistical significance in the subgroup of patients undergoing PCI or in analyses confined to randomized controlled trials. 8 An import caveat, however, is that the rates of major adverse cardiac events in the individual studies included in the meta-analysis were driven predominantly by myocardial infarctions, many of which were due to infarcts caused by the PCI itself. Recent evidence suggests that many post-PCI biomarker elevations are clinically insignificant, so less useful for endpoint analyses. 9 The results of this meta-analysis add weight to a growing body of evidence suggesting that it is safe to defer administration of ADP-receptor antagonists while continuing aspirin and anticoagulation therapy to patients with non-ST elevation ACS being treated with an early invasive strategy until after the coronary anatomy has been defined. For the approximate 20% of patients who are found to need surgical revascularization, the avoidance of ADP-receptor antagonist exposure would facilitate a timelier and undoubtedly safer surgical procedure. 10 Competing interests: I have read and understood the BMJ Group policy on declaration of interests and declare the following interests: none.
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